logo
Plus   Neg
Share
Email

Donaldson Trims FY19 Outlook - Quick Facts

While reporting financial results for the third quarter, Donaldson Co. Inc. (DCI) lowered its earnings and sales growth guidance for the full-year 2019.

For fiscal 2019, Donaldson now expects earnings in a range of $2.20 to $2.24 per share, compared to the prior guidance range of $2.27 to $2.41 per share.

The company also now expects full-year sales to increase between 3.5 and 4.5 percent, which includes a negative impact from currency of about 3 percent and a benefit from BOFA of 1 percent.

The midpoint of the revised sales guidance range is about 3 percent below prior guidance, driven by changes to the Aftermarket, Off-Road and IFS forecasts. Sales forecasts for all other business units are consistent with prior guidance.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $2.33 per share on sales growth of 7.1 percent to $2.93 billion for the year. Analysts' estimates typically exclude special items.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Global PC shipments returned to growth in the second quarter of 2020 after seeing a significant decline in the preceding first quarter due to COVID-19 related supply-chain disruptions, according to reports by two research firms. The PC market returned to growth in the quarter as production ramped up and vendors restocked their supplies to near-normal levels. The bankruptcy filing of America's oldest apparel retailer Brooks Brothers has ignited significant interest from potential buyers for the brand. WHP Global and a venture backed by Authentic Brands Group LLC and Simon Property Group, Inc., are reportedly considering bids for the retailer. WHP Global owns the ANNE KLEIN and JOSEPH ABBOUD brands. Sundial Herbal Products has recalled around 65 products, which were misbranded and currently unapproved drugs, the U.S. Food and Drug Administration said in a statement. The recall follows an order by a federal judge in June to stop distributing the company's unapproved new drugs. The affected items include herbal products and dietary supplements.
RELATED NEWS
Follow RTT